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Abstract
Background: Interleukin-8 (IL-8/CXCL-8) is a prototype of the ELR+CXC chemokines that play an important role in the 
promotion and progression of many human cancers including breast cancer. We have recently showed the implication 
of polymorphism (-251) T/A of IL-8 gene in the susceptibility and prognosis of breast carcinoma. IL-8 acts through its 
CXCR1 and CXCR2 receptors. CXCR2, expressed on the endothelial cells, is the receptor involved in mediating the 
angiogenic effects of ELR+CXC chemokines and in particular IL-8.
In the current study, we investigated the susceptibility and prognostic implications of the genetic variation in CXCR2 in
breast carcinoma. We also confirmed the implication of IL-8 (-251) T/A polymorphism in a larger cohort. Finally, we
combined the IL-8 and CXCR2 variant alleles and analyzed their effects in breast cancer risk and prognosis.
Methods: We used the allele-specific polymerase chain reaction to characterize the variation of IL-8 and CXCR2 for 409 
unrelated Tunisian patients with breast carcinoma and 301 healthy control subjects. To estimate the relative risks, Odds 
ratios and 95% confidence intervals were calculated using unconditional logistic regression after adjusting for the 
known risk factors for breast cancer. Associations of the genetic marker with the rates of breast carcinoma-specific 
overall survival and disease-free survival were assessed using univariate and multivariate analyses.
Results: A highly significant association was found between the homozygous CXCR2 (+ 1208) TT genotype (adjusted 
OR = 2.89; P = 0.008) and breast carcinoma. A significantly increased risk of breast carcinoma was associated with IL-8 (-
251) A allele (adjusted OR = 1.86; P = 0.001). The presence of two higher risk genotypes (the TA and TT in IL-8, and the TT 
in CXCR2) significantly increased the risk of developing breast carcinoma (adjusted OR = 4.15; P = 0.0004).
The CXCR2 (+ 1208) T allele manifested a significant association with an aggressive phenotype of breast carcinoma as
defined by a large tumor size, a high histological grade, and auxiliary's lymph node metastasis. A significant association
between the IL-8 (-251) A allele and the aggressive form of breast carcinoma was also found.
Moreover, the presence of the IL-8 (-251) A and/or the CXCR2 (+ 1208) T allele showed a significant association with a
decreased overall survival and disease-free survival in breast carcinoma patients.
Conclusion: Our results indicated that the polymorphisms in IL-8 and CXCR2 genes are associated with increased 
breast cancer risk, as well as disease progress, supporting our hypothesis for IL-8 and ELR+CXC chemokine receptor 
(CXCR2) involvement in breast cancer pathogenesis.
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Background
Breast cancer is one of the most prevalent cancers in the
world. Despite progress made in the last 30 years in
breast cancer screening and treatment, this disease is still
responsible for almost half a million deaths per year
worldwide. Approximately half of diagnosed patients will
eventually develop metastatic disease. Treatment for
metastatic breast cancer is palliative, and median life
expectancy after recurrence is between 24 and 30 months
or less [1,2].
The etiology of breast cancer is extremely complex and,
while not yet elucidated, appears to involve numerous
genetic, endocrine and external environmental factors.
The role of genetic factors in epidemiology and patho-
genesis of both sporadic and familial breast cancer is now
well established. Only a small minority (~5%) of patients
with breast cancer develop the disease as a result of
inheritance of germline mutations in dominant, highly
penetrant susceptibility genes such as BRCA1  and
BRCA2. However, polymorphisms in the genes involved
in the complex mechanisms of carcinogenesis may confer
low penetrant susceptibility to breast cancer in a signifi-
cant proportion of the remaining patients [3].
The neoplastic transformation, growth, survival, inva-
sion, and metastases are dependent on the establishment
of a pro-angiogenic environment. Local angiogenesis is
determined by an imbalance in the over-expression of
pro-angiogenic factors, as compared to inhibitors of
angiogenesis. The CXC chemokine family is the unique
group of cytokines known for their ability to behave in a
disparate manner in angiogenesis regulation. Several
members of the CXC chemokine are potent promoters of
angiogenesis, whereas others inhibit the angiogenic pro-
cess. The disparity in angiogenic activity among CXC
chemokine family members is attributed to three amino
acid structural domains at the N terminus, Glu-Leu-Arg
(ELR), which is present in angiogenic (i.e., CXCL1,
CXCL2, CXCL3, CXCL5, CXCL6, CXCL7, and CXCL8)
[4-6], but not angiostatic (i.e., CXCL4, CXCL9, CXCL10,
and CXCL11) CXC chemokines [7].
ELR+ CXC chemokines play an important role in tumor
growth and progression in a number of tumor model sys-
tems [8]. In particular, interleukin-8 (IL-8/CXCL8),
which was originally described as a leukocyte chemoat-
tractant [9], was subsequently found to possess mitogenic
and angiogenic properties [10,11]. Several studies sug-
gested a tendency toward the involvement of IL-8 in can-
cer development [12]. Elevated IL-8 levels were
associated with disease progression and recurrence in
human prostate, lung, gastric, and breast cancers [13-16].
All angiogenic ELR+ CXC chemokines mediate their
angiogenic activity through CXCR2 [17]. Subsequent
studies have confirmed the expression of CXCR2, not
CXCR1, to be the primary functional chemokine receptor
in mediating endothelial cell chemotaxis [18,19]. By con-
sidering the expression of IL-8 by breast cancer cells and
CXCR2 by large vessel and microvascular endothelial
cells [19,20], an autocrine effect for IL-8 and the
chemokine receptor CXCR2 has been suggested.
Promoter regions of a number of cytokine genes con-
tain polymorphisms that directly influence cytokine pro-
duction [21]. The IL-8 gene is located on chromosome
4q13-21 and consists of four exons, three introns, and a
proximal promoter region [22]. Several polymorphisms
have been reported in the IL-8 gene. Interestingly, IL-8
production can be controlled by the -251 A/T in the pro-
moter region of this chemokine [23]. Recent data
revealed that the IL-8 (-251) A allele is associated with a
high expression level of IL-8 protein and a severe neutro-
phil infiltration [23].Other studies also reported that the
IL-8 (-251) T/A polymorphism is associated with a higher
risk of developing malignant diseases [24-27].
Three single polymorphisms at positions +785 C/T,
+1208 T/C and +1440 G/A were reported in the CXCR2
gene [28]. Several reports indicated that the polymor-
phism +1208 C/T which is located in the non-coding
region of CXCR2 gene might provide valuable informa-
tion for the pathogenesis and the susceptibility to chronic
inflammatory disease [28,29].
Previously we have reported an elevated risk for breast
cancer among the Tunisian population (n = 308 cases and
n = 236 healthy controls) associated with the IL-8 (-251)
T/A polymorphism. The implication of this polymor-
phism in the prognosis of breast carcinoma has also been
demonstrated [30].
Based on the abundant evidence for the role of IL-8 and
CXCR2 in carcinogenesis, we evaluated in this study the
association of CXCR2 (+ 1208) C/T gene polymorphism
and breast cancer susceptibility and prognosis in Tunisia.
Then we used existing and additional genotype data on
409 breast cancer cases and 301 healthy controls to exam-
ine the potential contribution of the combined genotypes
of IL-8 and CXCR2 in breast carcinoma occurrence, clin-
ico-pathological characteristics and prognosis.
Methods
Patients and controls
IL-8  and  CXCR2 genotype and allele frequencies were
determined in a group of 301 control subjects and 409
patients with breast carcinoma. Controls and patients
were selected from the same population living in the mid-
dle coast of Tunisia and including unrelated subjects.
Data on patient, tumour and treatment characteristics
at the study entry for each subject were collected from
the department of Radiation Oncology and Medical
Oncology of Sousse Hospital (Sousse, T unisia) between
1996 and 2004. They were selected consecutively when-
ever practically feasible.Snoussi et al. BMC Cancer 2010, 10:283
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All patients included in this study had primary breast
carcinoma, with unilateral breast tumours and with no
family history for the disease. The diagnosis of cancer
was confirmed by histopathological analyses. The
patients (n = 409) had a mean age of 48.0 ± 24.3 (SD)
years. At time of analysis, 88 patients experienced recur-
rence (local or distant). Among them, 56 died from breast
carcinoma (63.64%). Table 1 shows the treatment
description of all patients. A total of 301 healthy women
having a mean age of 48.0 ± 14.9 years, were blood donors
with no evidence of any personal or family history of can-
cer (or other serious illness). Samples from healthy con-
trols were collected consecutively between 1996 and
2004. Control individuals were frequency matched to the
expected age distribution of the cases and were from the
same geographical area. General characteristics of breast
cancer patients and healthy controls women are summa-
rized in Table 1.
A detailed description of the clinico-pathological char-
acteristics of breast cancer cases has been reported else-
where [31] and data on tumor size at diagnosis, nodal
status and histological grade are briefly included in Table
2.
Both patients and controls gave their written consent to
participate in the study and to allow their biological sam-
ples to be genetically analyzed. Approval for the study
was given by the National Ethical Committee.
Genomic DNA Extraction
Genomic DNA was extracted from peripheral blood leu-
kocytes by a salting procedure [32]. Briefly, 10 ml of
blood was mixed with triton lysis buffer (0.32 M sucrose,
1% Triton X-100, 5 mM MgCl2, H2O, 10 mM Tris-HCl,
pH 7.5). Leukocytes were spun down and washed with
H2O. The pellet was incubated with proteinase K at 56°C
and subsequently salted out at 4°C using a substrate NaCl
solution. Precipated proteins were removed by centrifu-
gation. The DNA in supernatant fluid was precipated
with ethanol. The DNA pellet was dissolved in 400 μl
H2O.
IL-8 (-251) T/A and CXCR2 (+1208) C/T genotyping
An allele-specific polymerase chain reaction (AS-PCR)
was used to detect the polymorphisms at positions -251
of IL-8 gene and +1208 of CXCR2 gene. For CXCR2 geno-
typing, 10 μl of PCR reaction mixture consisting of 50 ng
of genomic DNA, 0.01 mM dNTPs, 2 mM MgCl2, 1× Taq
polymerase buffer, 0.75 μM of each specific/common
primer (Amersham, Paris, France), 0.2 μM of each inter-
nal control primer (see Table 3 for primer sequences) and
0.5 U of Taq DNA polymerase (Amersham, Paris, France)
were employed. As an internal control, the Beta-globin
specific primers were included in the AS-PCR (Table 2).
First, a touch-down procedure 25 s at 95°C was carried
out. This was followed by annealing for 45 s at tempera-
tures decreasing from 66°C (four cycles) to 60°C (25
cycles) and an extension step at 72°C for 40 s. The geno-
types of IL-8 (-251) T/A marker were determined as pre-
viously reported [30].
The reaction products of IL-8 and CXCR2 gene amplifi-
cation were loaded onto 2% agarose gel containing ethid-
ium bromide, electrophoresed and visualized under UV
transillumination. To ensure quality control of all geno-
typing results, 25% of randomly selected samples of both
cases and controls were analysed a second time, without
finding any discrepancies.
Statistical analyses
The genotype and allele frequencies of IL-8 and CXCR2
were tested for the Hardy-Weinberg equilibrium for both
patient and control groups using the chi-square test.
Two-sample t tests and Chi-square tests were used to
explore the bivariate association between the status of
breast cancer and other covariates for continuous and
categorical variables, respectively. Risk association
between the genotypes and breast cancer susceptibility
and tumours characteristics was estimated by odds ratio
(OR) and 95% confidence intervals (95% CI) using multi-
variate logistic regression analysis. The model for
adjusted OR included age at diagnosis, history of benign
breast disease, use of oral contraceptive, and body mass
index (BMI).
Table 1: The general characteristics of breast cancer 
patients and healthy controls from Tunisian women blood 
donors
Characteristics, n (%)a Cases Controls P-valueb
Ageb, yr
Mean ± SD 48.0 ± 24. 48.0 ± 14.9 0.97
Body mass index (BMI,
kg/m2)
24.1 ± 5.4 20.6 ± 2.5 0.0004
History of benign breast 
disease
No 241 (58.92) 154 (45.18)
Yes 168 (41.08) 147 (54.82) 0.039
Use of oral 
contraceptive
No 143 (34.96) 141 (46.84)
Yes 266 (65.04) 160 (53.16) 0.001
a Cases: n = 409; Controls: n = 301. The percentages were shown in the 
parentheses
b Age and BMI were determined by two-sample t tests; history of 
benign breast disease and oral contraceptive drugs usage were 
determined by chi-square tests.Snoussi et al. BMC Cancer 2010, 10:283
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Disease-free survival (DFS) was defined as the time
from the date of diagnosis to the first local or distant
recurrence or to last contact. Breast carcinoma-specific
overall survival (OVS) was defined as the time from the
date of diagnosis to death if the patient died from breast
carcinoma or to last contact. Six-year survival rates were
estimated, and survival curves were plotted according to
Kaplan and Meier [33]. The differences between groups
were calculated by the log-rank test [34].
In multivariate analysis, relative risk of recurrence or
death from breast carcinoma, 95% confidence intervals,
and P values for censored survival data were calculated by
use of Cox proportional hazards regression Model [35].
All P value calculations were two-sided, and P value was
considered significant at less than 0.05. Only clinico-
pathologic parameters bearing prognostic significance
were included in the Cox model. Clinicopathological
parameters were dichotomised as follows: nodal status
(≥1 versus no positive lymph node), SBR (Scarff, Bloom
and Richardson) tumour grade (1-2 versus  3), clinical
tumour size (T1-T2 versus T3-T4).
The statistical analysis was performed using SEM-
STATISTIQUES software (centre Jean Perrin, Clermont-
Ferrand, France).
Results
Polymorphisms in the IL-8 and CXCR2 genes as risk factors 
for breast carcinoma
The breast cancer patients (n = 409) and healthy controls
(n = 301) were all native Tunisian women. The character-
istics of the healthy controls and breast cancer patients,
including overage ages, body mass index (BMI), history of
benign breast disease, and oral contraceptives usage were
summarized in Table 1. There were no significant differ-
Table 2: Clinicopathologic Characteristics of the 409 Breast Carcinoma and the Corresponding Univariate Analysis of 
death (OVS) and Reccurencea (DFS)
Breast carcinoma specific OVS DFS
Characteristic % 6-year rate P-value 6-year rate P-value
Clinical tumor size
T1-T2 67.08 82.85 70
T3-T4 32.92 62.86 < 0.001 32.86 < 0.000001
Lymph node statusb
N (+) 46.72 84.23 71.43
N (-) 53.28 68.57 < 0.01 44.28 < 0.00001
SBR grading
1-2 60.87 79.28 69.10
3 40.13 57.28 < 0.02 47.80 < 0.01
Age (yrs)
< 50 57.32 78.1 70.0
≥50 42.68 75.71 NS 67.2 NS
OVS: overall survival; DFS: disease free survival; SBR: Scarff, Bloom and Richardson; NS: not significant.
aSix-year survival rates were estimated according to Kaplan and Meier. The log rank test was used to determine whether significant 
differences (P value) were observed between subgroups of patients.
bDetermined based on the pathologic examination.
Table 3: Primer sequences used for genotyping of IL-8 (-
251) T/A and CXCR2 (+1208) C/T gene polymorphisms (rs 
4073 and rs 1801032)
Primer name Primer sequence
IL-8 (-251) Common 5'-AAT ACG GAG TAT GAC GAA A-3'
IL-8 (-251) T (low expresser) 5'-CTA GAA ATA AAA AAG CAT ACA T-3'
IL-8 (-251) A (high 
expresser)
5'-CTA GAA ATA AAA AAG CAT ACA A-3'
HGH I CONTROL 5'-GCC TTC CCA ACC ATT CCC TTA-3'
HGH II CONTROL 5'-TCA CGG ATT TCT GTT GTG TTT-3'
CXCR2 (+1208) Common 5'-GTC TTG TGA ATA AGC TGC TAT GA-3'
CXCR2 (+1208) C Allele 5'-CCA TTG TGG TCA CAG GAA GC-3'
CXCR2 (+1208) T Allele 5'-CCA TTG TGG TCA CAG GAA GT-3'
Beta Globin I 5'-ACA CAA CTG TGT TCA CTA-3'
Beta Globin II 5'-CAA CTT CAT CCA CGT TCA CC-3'
HGH I and II primers amplify HGH (human growth hormone) 
sequence.Snoussi et al. BMC Cancer 2010, 10:283
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ences between cases and controls concerning age. How-
ever, BMI, history of benign breast disease, and oral
contraceptives usage were significantly different between
cases and controls after the statistical testing (see materi-
als and methods). These confounding factors were
adjusted in multivariate logistic regression analysis.
The genotype distribution and allele frequencies for the
IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms
in all breast carcinoma patients and controls are pre-
sented in Table 4. The allele frequencies of IL-8  and
CXCR2  genes were in Hardy-Weinberg equilibrium in
both patients and controls (P = , P = , P = , P = respec-
tively).
A significantly higher risk for breast cancer was
observed for carriers of IL-8  (-251) AA genotype
(adjusted Odds Ratio (OR) = 2.03; P = 0.001) and carriers
of IL-8 (-251) TA genotype (OR = 1.71; P = 0.009). The IL-
8 (-251) A allele was significantly higher in patients com-
pared to controls (OR = 1.86; P = 0.001).
The genotype frequency of the CXCR2 (+1208) TT was
0.115 in patients with breast carcinoma and 0.06 in con-
trol subjects (OR = 2.89; P = 0.008). The CXCR2 (+1208)
T allele was significantly higher in patients compared to
controls (OR = 1.37; P = 0.03) (Table 4).
Because IL-8 functionally interacts with CXCR2 we
assessed the effect of multiple genotypes on breast carci-
noma risk. Through individual investigations of geno-
types, we defined IL-8 (-251) TA, IL-8 (-251) AA, and
CXCR2 (+1208) TT as high-risk genotypes.
Table 5 shows the relation between ORs and the num-
ber of high-risk genotypes. In controls, there were no
high-risk genotypes in 26.91%, 1 in 68.44% and 2 in
4.65%. However, in breast cancer patients, there were no
high-risk genotypes in 18.3%, 1 in 71.7% and 2 in 10.02%.
The presence of 1 or 2 high-risk genotypes significantly
increased the risk of developing breast carcinoma, with
ORs of 1.63 (95% CI, 1.13 - 2.59; P = 0.01) and 4.15 (95%
CI, 1.92 - 7.32; P = 0.0004), respectively, compared with
the absence of the high-risk genotype.
Prognostic significance of polymorphism in IL-8 and CXCR2 
genes
Table 2 shows the clinicopathological characterization.
The distribution of the clinicopathological markers was
in accordance with previously reported data, indicating
that our cohort was representative of breast carcinoma
patients. Disease-free survival and breast carcinoma-spe-
cific OVS rates were estimated and compared by univari-
ate analysis on these clinicopathological parameters.
Significant associations were found for clinical tumor
size, lymph node status, and tumor grading with DFS and
OVS. No significant differences were observed for age.
The distributions of IL-8 and CXCR2 polymorphisms
according to the clinico- pathological indices of breast
carcinoma severity are presented in Tables 6 and 7. A sig-
Table 4: The IL-8 (-251) T/A and CXCR2 (+1208) C/T genotype distributions in Control Subjects and in Patients with Breast 
Carcinoma
Genotypes Patients (n = 409) Controls (n = 301) Crude OR (95% CI) P-valuea Adjusted OR (95% CI)b P-value
n (%) n (%)
IL-8 (-251)T/A
TT 84 (20.5) 92 (30.6) 1 1
TA 201 (49.2) 138 (45.8) 1.60 [1.09-2.34] 0.01 1.71 [1.13-2.55] 0.009
AA 124 (30.3) 71 (23.6) 1.91 [1.24-2.96] 0.002 2.03 [1.56-3.67] 0.001
Alleles
T-allele 369 (45.1) 322 (53.5)
A-allele 449 (54.9) 280 (46.5) 1.40 [1.13-1.74] 0.001 1.86 [1.79-2.45] 0.001
CXCR2 (+1208)C/T
CC 195 (46.7) 155 (51.5) 1 1
CT 167 (40.8) 128 (42.5) 1.04 [0.75-1.43] 0.81 1.31 [0.90-1.69] 0.63
TT 47 (11.5) 18 (6.0) 2.08 [1.12-3.88] 0.01 2.89 [1.48-4.55] 0.008
Alleles
C-allele 557 (6.81) 438 (7.28)
T-allele 261 (31.9) 164 (27.2) 1.25 [0.99-1.59] 0.05 1.37 [1.09-1.88] 0.03
a P-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.Snoussi et al. BMC Cancer 2010, 10:283
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nificant association between IL-8 (-251) A allele and large
tumor size (T3-T4), high SBR tumor grade (grade 3), and
lymph node metastases was observed (Table 6). In this
analysis, we also observed the association of this poly-
morphism with the hormone status of breast carcinoma.
Interestingly, a pronounced association was found
between the IL-8 (-251) A allele and a negative hormone
status (OR = 1.82; P = 0.0008).
Furthermore, the frequency of the CXCR2 (+1208) T
allele was significantly higher in patients with a large
tumor size (OR = 1.98; P = 0.0001), with high SBR tumor
grade (grade 3) (OR = 1.67; P = 0.01), and with lymph
node metastases (OR = 1.83; P = 0.0008). Taken together,
these results suggest that the (-251) A allele of the IL-8
gene and the (+1208) T allele of the CXCR2 gene are asso-
ciated with the aggressive forms of breast carcinoma. No
association was found between CXCR2  gene polymor-
phism and the hormone status of breast cancer patients
(Table 7).
When the relationship between the distribution of IL-8
and  CXCR2  genotypes in all patients and the survival
(OVS and DFS) was tested, significant differences were
observed between the OVS and the DFS Kaplan-Meier
survival curves for the different polymorphisms.
The breast carcinoma-specific OVS was significantly
shorter among patients carrying the IL-8 (-251) A allele
(Figure 1A). The estimated 3- and 6-year breast carci-
noma-specific OVS rates for the group of patients carry-
ing or not carrying the IL-8  (-251) A allele were
respectively 91.4 and 77.1% versus 75.7 and 45.7% (log
rank test, P < 0.002). The estimated 3- and 6-year DFS
rates in the group of patients with IL-8 (-251) A allele
were 81.4% and 50% versus 95.7% and 88.5% in the group
of patients without the IL-8 (-251) A allele (log rank test,
P < 0.001).
As shown in Figure 2, the breast carcinoma specific
OVS and DFS were significantly shorter in the group of
patients carrying CXCR2 (+1208) T allele. The estimated
3- and 6-year breast carcinoma OVS rate in the group of
patients carrying CXCR2 (+1208) T allele were, respec-
tively, 87.1 and 65.7% versus 95.7% and 90% for those not
carrying the (+1208) T allele (log rank test, P < 0.001).
The estimated 3- and 6-year DFS rates in the group of
patients with CXCR2 (+1208) T allele were 74.3% and
50% versus 90% and 61.4% in the group of patients with-
out the CXCR2 (+1208) T allele (log rank test, P < 0.01).
Multivariate analyses were undertaken to evaluate the
importance of IL-8 and CXCR2 markers in the recurrence
risk and death compared with the clinicopathological
parameters. Introducing the genetic and the clinico-
pathological parameters bearing prognostic significance
we tested the Cox model. No genetic and clinicopatho-
logical parameters were selected for OVS and DFS.
Further analyses were conducted to explore whether
combined high-risk genotypes of the IL-8  and  CXCR2
genes were associated with clinicopathological indices
and survival among patients. No additional effect was
found between the presence of more than one high-risk
genotype and indices of an aggressive form of breast car-
cinoma (nodal status, SBR, tumor grade) or OVS and DFS
(data not shown).
Discussion
The ELR+ CXC chemokines play an important role in
tumor growth and progression in a number of tumor
model systems. IL-8/CXCL8 was the first described
angiogenic, mitogenic, and motogenic chemokine in vari-
ous cancer models and is the prototype of ELR+ CXC
chemokines [8,10-13]. This chemokine was initially dis-
covered on the basis of its ability to induce mobilization
of neutrophils and lymphocytes in vivo [9]. Like the basic
fibroblast growth factor (bFGF) and the vascular
endothelial growth factor (VEGF), it is a strong angiogen-
esis inducer. IL-8 mediates endothelial cell chemotaxis
and proliferation in vitro and in vivo [36].
The fact that all ELR+CXC chemokines mediate angio-
genesis highlights the importance of identifying a com-
mon receptor that mediates their biological functions in
promoting angiogenesis. The candidate CXC chemokine
receptors are CXCR1 and CXCR2. Only CXCL-8/IL-8
and CXCL-6 specifically bind to CXCR1 whereas all
ELR+CXC chemokines bind to CXCR2. There is evidence
Table 5: Interaction and addictive effects of IL-8 (-251) T/A and CXCR2 (+1208) C/T polymorphisms on breast cancer risk
Genotypes Patients (n = 409) Controls (n = 301) Crude OR (95% CI) P-valuea Adjusted OR (95%)b P-value
IL-8 (-251)/CXCR2 (+1208) n % n %
0 75 (18.34) 81 (26.91) 1 1
1 293 (71.64) 206 (68.44) 1.54 [1.05-2.24] 0.01 1.63 [1.13-2.59] 0.01
2 41 (10.02) 14 (4.65) 3.16 [1.52-6.64] 0.0006 4.15 [1.92-7.32] 0.0004
a P-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.
The high risk genotypes: IL-8 (-251) T/A = TA/AA; CXCR2 (+1208) C/T = TTSnoussi et al. BMC Cancer 2010, 10:283
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that CXCR2 is implicated in the angiogenic activity of
ELR+ CXC chemokines [18,36].
In recent years, several studies have shown that IL-8
and CXCR2 are overexpressed in a range of human can-
cers including renal, prostate, pancreatic, colon, nasopha-
ryngeal, and gastric cancers [37-41]. IL-8 and its
receptors were detected on breast tumor cells and
endothelial cells of tumor vessels [19-21]. In addition, IL-
8 levels are significantly higher in breast cancer patients
compared with healthy controls [42]. Ben-Baruch et al
have demonstrated that, aside the role of IL-8 and
CXCR2 in mediating the recruitment of the tumor-infil-
trating leucocytes to tumor site, their expression may also
affect neoplastic proliferation and metastasis [43].
IL-8 and CXCR2 overexpression may present a risk fac-
tor in the development and progression of solid tumors.
Several polymorphisms have been identified in IL-8 and
CXCR2 genes. Among these, IL-8 (-251) T/A polymor-
phism exerts one of the greatest influences on IL-8 pro-
duction. Polymorphism +1208 C/T of the CXCR2 gene is
implicated in the susceptibility to and the pathogenesis of
chronic inflammatory diseases [28,29].
Recently, we have showed that IL-8 (-251) T/A poly-
morphism may be a genetic risk factor for breast cancer
onset and severity in the Tunisian population [30]. Our
Table 6: Genotype frequencies of IL-8 (-251) T/A polymorphism in relation to pathological indices of Breast Cancer severity
Genotypes Number of patients (%) Crude OR (95% CI) P-valuea Adjusted OR (95% CI)b P-value
Clinical tumor size T1-T2 T3-T4
TT 65 (27.08) 37 (24.51) 1 1
TA 122 (50.84) 58 (38.41) 0.84 [0.49-1.44] 0.48 0.74 [0.67-1.32] 0.87
AA 53 (22.08) 56 (37.08) 1.86 [1.03-3.35] 0.02 1.79 [1.11-3.76] 0.01
Alleles
T-allele 252 (52.50) 132 (43.71)
A-allele 228 (47.50) 170 (56.29) 1.42 [1.05-1.92] 0.01 1.57 [1.32-2.05] 0.01
Lymph nodes status Negative Positive
TT 50 (27.62) 42 (19.91) 1 1
TA 92 (50.83) 95 (45.02) 1.46 [0.85-2.52] 0.14 1.32 [0.78-2.01] 0.21
AA 39 (21.55) 74 (35.07) 2.26 [1.24-4.14] 0.004 2.59 [1.47-5.32] 0.002
Alleles
T-allele 192 (53.04) 179 (42.42)
A-allele 170 (46.96) 243 (57.58) 1.53 [1.14-2.05] 0.002 1.58 [1.28-2.24] 0.001
SBR grading 1-2 3
TT 66 (32.19) 46 (28.22) 1 1
TA 111 (54.15) 67 (41.11) 0.87 [0.52-1.45] 0.55 0.91 [0.58-1.49] 0.34
AA 28 (13.66) 50 (30.67) 2.56 [1.35-4.87] 0.001 2.69 [1.52-5.24] 0.0009
Alleles
T-allele 243 (59.27) 159 (48.77)
A-allele 167 (40.73) 167 (51.23) 1.53 [1.13-2.07] 0.004 1.66 [1.38-2.79] 0.002
Estrogen receptor status Negative Positive
TT 41 (23.7) 51 (41.13) 1 1
TA 75 (43.35) 44 (35.48) 2.12 [1.17-3.84] 0.007 2.01 [1.32-3.76] 0.006
AA 57 (32.95) 29 (23.39) 2.44 [1.28-4.70] 0.003 2.56 [1.68-4.96] 0.001
Alleles
T-allele 157 (45.38) 146 (58.87)
A-allele 189 (54.62) 102 (41.13) 1.72 [1.22-2.48] 0.001 1.82 [1.96-2.78] 0.0008
a P-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.Snoussi et al. BMC Cancer 2010, 10:283
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current study aims to confirm these results in a larger
cohort and to determine whether there is any association
between the genetic polymorphism of the CXCR2 and
both individual susceptibility to and prognosis of breast
carcinoma. Based on the intertwined and interactive roles
that IL-8 and CXCR2 play at the molecular level in the
angiogenic pathway, we further hypothesized a priori that
the joint effect of genetic variants in these angiogenesis
regulators may increase breast cancer risk.
In the present study, the comparison of genotype fre-
quencies of IL-8 for breast carcinoma patients and con-
trol subjects indicates an increase of IL-8 (-251) TA and
AA genotypes. Consequently, the IL-8 (-251) A allele fre-
quency was found to be significantly higher in patients
compared with controls. These results confirmed our
previous findings in a smaller subset of cases and controls
[31].
CXCR2  g e n o t y p e  a n a l y s i s  r e v e a l e d  t h a t  c a r r i e r s  o f
CXCR2  (+1208) TT homozygous genotype are signifi-
Table 7: Genotype frequencies of CXCR2 (+1208) C/T polymorphism in relation to pathological indices of Breast Cancer 
severity
Genotypes Number of patients (%) Crude OR (95% CI) P-valuea Adjusted OR (95% CI)b P-value
Clinical tumor size T1-T2 T3-T4
CC 117 (48.75) 51 (33.55) 1 1
CT 89 (37.08) 62 (40.79) 1.60 [0.98-2.61] 0.04 1.73 [1.01-2.76] 0.03
TT 34 (14.17) 39 (25.66) 2.63 [1.44-4.82] 0.0006 2.89 [1.64-5.06] 0.0004
Alleles
C-allele 323 (67.29) 164 (53.95)
T-allele 157 (32.71) 140 (46.05) 1.76 [1.29-2.39] 0.0001 1.98 [1.47-2.56] 0.0001
Lymph nodes status Negative Positive
CC 94 (51.93) 81 (38.39) 1 1
CT 69 (38.12) 89 (42.18) 1.50 [0.95-2.36] 0.06 1.45 [0.98-2.27] 0.07
TT 18 (9.95) 41 (19.43) 2.64 [1.35-5.21] 0.002 2.72 [1.44-5.43] 0.001
Alleles
C-allele 257 (70.99) 251 (59.48)
T-allele 105 (29.01) 171 (40.52) 1.67 [1.22-2.27] 0.0007 1.83 [1.32-2.46] 0.0008
SBR grading 1-2 3
CC 91 (44.39) 63 (38.18) 1 1
CT 85 (41.46) 64 (38.78) 1.09 [0.67-1.76] 0.71 1.12 [0.78-1.89] 0.65
TT 29 (14.15) 38 (23.03) 1.89 [1.02-3.53] 0.03 1.98 [1.15-3.79] 0.02
Alleles
C-allele 267 (65.12) 190 (57.58)
T-allele 143 (34.88) 140 (42.42) 1.38 [1.01-1.87] 0.03 1.67 [1.08-2.03] 0.01
Estrogen receptor status Positive Negative
CC 50 (30.87) 48 (33.33) 1 1
CT 76 (46.91) 60 (41.67) 1.22 [0.70-2.12] 0.46 1.34 [0.78-2.34] 0.35
TT 36 (22.22) 36 (25.00) 0.96 [0.50-1.85] 0.89 0.87 [0.54-1.89] 0.85
Alleles
C-allele 176 (54.32) 156 (54.17)
T-allele 148 (45.68) 132 (45.83) 0.99 [0.71-1.38] 0.96 0.95 [0.66-1.27] 0.87
a P-value determined by χ2 test.
b ORs were adjusted for age, BMI, history of benign disease, and oral contraceptive drugs usage.Snoussi et al. BMC Cancer 2010, 10:283
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cantly over-represented among breast cancer cases (OR =
2.08; P = 0.01). Despite the great interest in CXCR2 bio-
logical properties, little is known about the functional
importance of single nucleotide polymorphisms in its
gene. This result indicates that CXCR2 gene polymor-
phism could be considered as a susceptibility gene in
breast cancer development.
These findings suggested that individual genetic poly-
morphisms of IL-8  and  CXCR2  were associated with
breast carcinoma risk. However, the combination of these
genotypes showed a marked association with breast car-
cinoma risk. We defined the TA and AA genotypes of the
IL-8 gene and the TT genotype of the CXCR2 gene as
high-risk genotypes according to the individual genotype
analysis. Breast carcinoma risk significantly increased
according to the number of high-risk genotypes. There
was a 63% increase in breast cancer (OR = 1.63; P = 0.01)
for the presence of one high-risk genotype. The risk was
4.15 (P = 0.0004) for individuals with two high-risk geno-
types. These data, taken together, suggest that there is
evidence of a gene-dosage effect.
The assessment of the prognostic value of IL-8 genetic
marker in breast carcinoma confirmed the results of our
previous study and indicated that IL-8 (-251) A allele is
highly associated with aggressive forms of breast carci-
noma as defined by large tumor size, high grade and
lymph node metastases. In the current study, we also
examined for the first time the relationship between IL-8
(-251) T/A polymorphism and the hormonal status.
Interestingly, we observed a significant association
between IL-8 (-251) A allele and a negative hormonal sta-
tus (P = 0.0008).
Furthermore, we investigated the association of the
CXCR2  (+1208) C/T polymorphism with markers of
tumor progression. Our results showed a significant asso-
ciation between CXCR2  (+1208) T allele and a large
tumor size (P = 0.0001), high SBR tumor grade (P = 0.01),
and lymph node metastases (P = 0.0008). More interest-
ingly, we showed that IL-8 (-251) A and CXCR2 (+1208) T
alleles were associated with a shorter overall survival and
disease-free survival and, therefore, with a poor progno-
sis in breast carcinoma.
Figure 1 Breast carcinoma-specific overall survival (A) and disease-free survival (B) of 409 breast carcinoma patients according to the pres-
ence or absence of IL-8 (-251) A allele (P denotes the log-rank test value).
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Figure 2 Breast carcinoma-specific overall survival (C) and disease-free survival (D) of 409 breast carcinoma patients according to the pres-
ence or absence of CXCR2 (+1208) T allele (P denotes the log-rank test value).
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Given the importance of IL-8 and CXCR2 in angiogen-
esis, we investigated the relationship between polymor-
phisms -251 T/A in IL-8 gene and (+1208) C/T in CXCR2
gene and breast carcinoma. The results show that these
polymorphisms may be related to breast carcinoma
development and progression.
In agreement with our findings, several studies
reported a relationship between IL-8  (-251) T/A and
CXCR2 (+1208) C/T genes polymorphisms and human
cancer. IL-8 (-251) A allele, which resulted in higher IL-8
secretion was associated with an increased risk and poor
prognosis of colorectal cancer, prostate cancer, and gas-
tric cancer [24-26,44]. Similarly, we reported in a previ-
ous study that IL-8 (-251) A allele held a higher risk of
nasopharyngeal carcinoma and was highly associated
with aggressive forms and poor prognosis [27]. Regarding
breast carcinoma, the current study confirmed our previ-
ous results obtained in a smaller cohort and is also in
agreement with Kamali-Sarvestani et al. who reported
that IL-8 (-251) A allele carriers had a significantly higher
risk of breast carcinoma than non carriers in the Iranian
population [45].
Recently, few studies have shown the relationship
between CXCR2 gene polymorphisms and human cancer
[46,47]. The CXCR2 gene polymorphisms were associ-
ated with pancreatic cancer but not with prostate and
breast cancer [46,47]. Kamali-Sarvestini et al. have dem-
onstrated that CXCR2 (+1208) C/T polymorphism is not
associated with breast cancer [45]. This result is in con-
trast with our findings.
There is now convincing evidence that these correla-
tions between IL-8 A allele and cancer risk result from an
increased level of IL-8 protein, which may have an impact
on cancer development and progression via the regula-
tion of immune response and pathways of tumor angio-
genesis.
IL-8 is an important chemoattractant that promotes
inflammatory processes [9]. The IL-8 receptors CXCR1
and CXCR2 have been reported to be present in a variety
of cell types including inflammatory cells, endothelial
cells, and fibroblasts [46]. Consequently, IL-8 is a major
contributing factor involved in the initiation and amplifi-
cation of the inflammatory response via its receptors [48].
However, it is known that inflammation profoundly
affects the development and progression of tumor and
therefore, IL-8 might promote tumor cell proliferation by
amplification of inflammation in the tumor microenvi-
ronnement via its receptors.
IL-8 proangiogenic effects additionally stem from its
ability to inhibit the apoptosis of endothelial cells [49].
This inhibition is associated with increased levels of the
anti-apoptotic factors Bcl-xl and Bcl-2 as well as with
decreased levels of Bax. It was further shown that IL-8
stimulates increased endothelial cell mRNA expression of
matrix metalloproteinases (MMPs) MMP-2 and -9 as well
as increases gelatine activity [49]. These MMP activities
are required for the proteolytic modifications of base-
ments membranes and extracellular matrices during
angiogenesis.
IL-8 was shown to act as an autocrine growth factor
and to stimulate invasion and chemotaxis of many tumor
cell types. The expression of IL-8 and the receptor of
ELR+CXC chemokine CXCR2 in cancer have been evalu-
ated in numerous studies. Overexpression of IL-8 is asso-
ciated with increasing tumor stage, disease progression
and recurrence in human bladder, prostate, breast, lung,
gastric, hepatic cancers, and melanoma [11,14-
16,43,50,51]. Recently, it has been shown that the ER-neg-
ative breast cancer cells overexpressed IL-8. Concerning
IL-8 receptors, it has been observed that CXCR1 expres-
sion was extremely low in breast cancer cells, whereas
most of the cells investigated showed a higher expression
of CXCR2 [52]. The same study also suggested that IL-8
expression is negatively correlated to ER-status and is
expressed preferentially in invasive cancer cells [52].
Moreover, our data showed that the higher percentage of
ER-negative tumors were present in patients carrying the
IL-8 (-251) A allele which is associated with a higher IL-8
production. Altogether, these results suggested that the
genetic variation in the promoter of the IL-8 gene which
influences the production of this chemokine could be the
genetic basis of the potential tumor progression and inva-
siveness of breast cancer.
The ability of IL-8 to elicit angiogenic activity depends
on the endothelial cell expression of its receptors. Recent
studies indicated that CXCR1 and CXCR2 are highly
expressed on human microvascular endothelial cells
(HMEC) [53]. Antibodies directed at CXCR1 and CXCR2
are capable of inhibiting IL-8 induced migration of
HMEC, which indicates that these two receptors are crit-
ical for the IL-8 angiogenic response. Since CXCR2 binds
to all ELR+CXC chemokines that induce angiogenesis,
including IL-8, it may be safe to say that CXCR2 is a
mediator of the proangiogenic effects of IL-8.
Several reports have confirmed the importance of
CXCR2 in mediating the effects of angiogenesis in human
microvascular endothelial cells [18,36,53]. Endothelial
cells were found to express CXCR2 in vitro and in vivo,
but not CXCR1. Blocking the function of CXCR2 by
either neutralizing antibodies or inhibiting downstream
signalling using specific inhibitors of ERK1/2 and PI3
kinase impaired IL-8-induced stress fiber assembly,
chemotaxis, and endothelial tube formation in endothe-
lial cells [39,54]. Overall, these data strongly support a
role for CXCR2 in angiogenesis induced by ELR+CXC
chemokines and especially by IL-8.Snoussi et al. BMC Cancer 2010, 10:283
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Conclusion
In summary, our data suggests that IL-8 (-251) T/A and
CXCR2 (+1208) C/T polymorphisms are likely to play a
major role in susceptibility to and prognosis in breast car-
cinoma. Although additional studies on a larger scale will
be required to confirm and extend our findings, the pres-
ent data suggest for the first time that CXCR2 (+1208) C/
T polymorphism represents a risk factor for poorer prog-
nosis and susceptibility to breast carcinoma. Further-
more, this study provides support for the multigenetic
effects of the variant alleles from IL-8, and CXCR2, result-
ing in a significantly increased risk for breast cancer in
the Tunisian population. Our findings also reinforce the
role attributed to inflammation, angiogenesis, and their
mediators as major contributing factors in the process of
breast tumor development, progression and aggressive-
ness. Using the IL-8 (-251) T/A and CXCR2 (+1208) C/T
polymorphisms alone or in combination with other
genetic polymorphisms in angiogenic and inflammatory
genes to predict breast carcinoma outcome and progno-
sis may therefore have an important clinical significance.
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